BOPI 11 BR/2024 REPERTOIRE NUMERIQUE 12 (11) 21688 Consulter le mémoire (51) A61K 31/439 (2018.01); A61P 11/00 (2018.01); A61P 43/00 (2018.01); C07D 498/18 (2018.01); C07D 498/18 (2018.01) ; C07D 513/22 (2018.01) (21) 1202300194 - PCT/US2021/072475 (22) 17/11/2021 (30) US n° 63/115, 552 du 18/11/2020 (54) Macrocycles Containing A 1, 3, 4Oxadiazole Ring For Use As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator. (72) CLEVELAND, Thomas (US); BAEK, Minson (US); CLEMENS, Jeremy, J. (US); BOOKSER, Brett C. (US); BECHARA, William Schulz (US); GALLANT, Michel (US) et COON, Timothy (US) (73) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, BOSTON, Massachusetts 02210 (US) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Formula I This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators. Fig. 1 ________________________________________ (11) 21689 Consulter le mémoire (51) A61L 26/00 (2018.01); A61L 27/36 (2018.01) ; A61L 27/50 (2018.01) (21) 1202300389 - PCT/IB2022/052776 (22) 25/03/2022
RkJQdWJsaXNoZXIy MTM1NDc3MA==